{"title":"艾司美沙酮在抑郁症三期试验中的结果喜忧参半","authors":"","doi":"10.1002/pu.31227","DOIUrl":null,"url":null,"abstract":"<p>A Phase 3 trial of esmethadone as adjunctive treatment for patients with treatment-resistant depression did not meet its primary endpoint of significant improvement in depressive symptoms at 28 days compared with placebo. Esmethadone did show significant improvement over placebo in treatment response rate.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"35 11","pages":"4"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Mixed results for esmethadone in Phase 3 depression trial\",\"authors\":\"\",\"doi\":\"10.1002/pu.31227\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>A Phase 3 trial of esmethadone as adjunctive treatment for patients with treatment-resistant depression did not meet its primary endpoint of significant improvement in depressive symptoms at 28 days compared with placebo. Esmethadone did show significant improvement over placebo in treatment response rate.</p>\",\"PeriodicalId\":22275,\"journal\":{\"name\":\"The Brown University Psychopharmacology Update\",\"volume\":\"35 11\",\"pages\":\"4\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Brown University Psychopharmacology Update\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/pu.31227\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Brown University Psychopharmacology Update","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pu.31227","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Mixed results for esmethadone in Phase 3 depression trial
A Phase 3 trial of esmethadone as adjunctive treatment for patients with treatment-resistant depression did not meet its primary endpoint of significant improvement in depressive symptoms at 28 days compared with placebo. Esmethadone did show significant improvement over placebo in treatment response rate.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
